Biocytogen has developed a series of humanized mouse models targeting PCSK9 and APOC3, along with cardiovascular and cerebrovascular disease models, to facilitate the evaluation of novel therapeutics.
on this page
Cardiovascular and cerebrovascular diseases represent a major cause of morbidity and mortality in clinics. To improve diagnostics, and to discover and test novel preventive and curative therapies, experimental models that recapitulate human disease are appealing to the researchers worldwide.
Biocytogen has developed a series of humanized mouse models targeting PCSK9 and APOC3, along with cardiovascular and cerebrovascular disease models, to facilitate the evaluation of novel therapeutics.
Humanized mouse models targeting PCSK9 and APOC3, and an atherosclerosis model based on ApoE KO mice, facilitate the evaluation of novel therapeutics.
Learn More
The Middle Cerebral Artery Occlusion (MCAO) model is a widely used preclinical tool that replicates ischemic stroke in humans, making it ideal for preclinical studies.
Learn More